Hans Bösmüller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hans Bösmüller has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Falko Fend
4 shared publicationsAnnette Staebler
2 shared publications- Christine Gruber
Department of Pathology, Krankenhaus Barmherzige Schwestern Linz, Austria
2 shared publications Gerald Webersinke
Krankenhaus Barmherzige Schwestern Linz
2 shared publications- Gerald Webersinke
Krankenhaus der Barmherzigen Schwestern Linz BetriebsgesmbH
2 shared publications Irina Bonzheim
2 shared publications
Latest Publications
- 1 March 2013
- Published by Elsevier in Human Pathology
- Vol. 44 (3) , 329-335
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR
- 1 March 2013
- Published by Elsevier in Human Pathology
- Vol. 44 (3) , 329-335
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR
- 17 August 2011
- Published by Springer Nature in Der Pathologe
- Vol. 33 (2) , 113-117
Mitosen bei frühinvasiven malignen Melanomen
Seit Anfang Februar 2010 wurde am Institut für Pathologie des Krankenhauses der Barmherzigen Schwestern die neue Stadieneinteilung bzw. Klassifikation des American Joint Committee on Cancer (AJCC) von 2009 in den diagnostischen Alltag übernommen. Da der Anzahl der Mitosen/mm2 nach diesen Richtlinien eine zentrale Bedeutung zufällt, konnten wir gemäß dieser Empfehlungen für Melanome im Stadium pT1 eine deutliche Verschiebung vom Stadium pT1a in das Stadium pT1b beobachten. Dies betraf verstärkt jene Tumoren, die sich in der Kategorie pT1a nach der Union-for-International-Cancer-Control(UICC)-Klassifikation (7. Aufl.) minimal-invasiv verhielten. Eine Zuordnung von Mitosen bei frühinvasiven Melanomen in Bezug auf einen möglichen epithelialen oder melanozytären Ursprung ist nicht immer eindeutig. Somit ist nicht auszuschließen, dass Melanome aus dem Stadium pT1a nach UICC aufgrund diagnostischer Unsicherheiten fälschlicherweise ins Stadium pT1b (AJCC) verschoben werden. Since early February 2010 we have been implementing the latest version of the 2009 AJCC Melanoma Staging and Classification in our institution. Since, according to the guidelines for stage pT1 melanomas, the number of mitoses/mm2 is of particular significance, we have been able to observe a notable shift from pT1a to pT1b. Highlighting the mitotic count as one of the key features of the diagnosis of malignant melanoma, we observed that the major part of stage-switched melanomas belonged to a minimally invasive subset of melanomas previously categorized as pT1a UICC (7th edition). A level of reasonable doubt remains regarding the distinct histogenetic classification of mitosis as early stage melanoma with regard to their epithelial or melanocytic origin.
- 17 August 2011
- Published by Springer Nature in Der Pathologe
- Vol. 33 (2) , 113-117
Mitosen bei frühinvasiven malignen Melanomen
Seit Anfang Februar 2010 wurde am Institut für Pathologie des Krankenhauses der Barmherzigen Schwestern die neue Stadieneinteilung bzw. Klassifikation des American Joint Committee on Cancer (AJCC) von 2009 in den diagnostischen Alltag übernommen. Da der Anzahl der Mitosen/mm2 nach diesen Richtlinien eine zentrale Bedeutung zufällt, konnten wir gemäß dieser Empfehlungen für Melanome im Stadium pT1 eine deutliche Verschiebung vom Stadium pT1a in das Stadium pT1b beobachten. Dies betraf verstärkt jene Tumoren, die sich in der Kategorie pT1a nach der Union-for-International-Cancer-Control(UICC)-Klassifikation (7. Aufl.) minimal-invasiv verhielten. Eine Zuordnung von Mitosen bei frühinvasiven Melanomen in Bezug auf einen möglichen epithelialen oder melanozytären Ursprung ist nicht immer eindeutig. Somit ist nicht auszuschließen, dass Melanome aus dem Stadium pT1a nach UICC aufgrund diagnostischer Unsicherheiten fälschlicherweise ins Stadium pT1b (AJCC) verschoben werden. Since early February 2010 we have been implementing the latest version of the 2009 AJCC Melanoma Staging and Classification in our institution. Since, according to the guidelines for stage pT1 melanomas, the number of mitoses/mm2 is of particular significance, we have been able to observe a notable shift from pT1a to pT1b. Highlighting the mitotic count as one of the key features of the diagnosis of malignant melanoma, we observed that the major part of stage-switched melanomas belonged to a minimally invasive subset of melanomas previously categorized as pT1a UICC (7th edition). A level of reasonable doubt remains regarding the distinct histogenetic classification of mitosis as early stage melanoma with regard to their epithelial or melanocytic origin.
- Open Access
- 14 July 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 65
Primary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient
Primary angiosarcoma of the ovary (AS) is a rare entity with only 31 reported cases. The majority are pure angiosarcomas, the remainder are associated either with teratomas or conventional epithelial tumors. More than 50% of ovarian AS are disseminated at the time of diagnosis, the minority is detected in stage I. The prognosis of ovarian angiosarcoma in general is poor. Most reports refer to younger individuals, aged from 7 to 46 years, and only 2 case reports could be found for patients older than 64 years. Here we present a very unusual case of angiosarcoma in a 81-year-old patient.
- 14 July 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 65
Open AccessPrimary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient
Primary angiosarcoma of the ovary (AS) is a rare entity with only 31 reported cases. The majority are pure angiosarcomas, the remainder are associated either with teratomas or conventional epithelial tumors. More than 50% of ovarian AS are disseminated at the time of diagnosis, the minority is detected in stage I. The prognosis of ovarian angiosarcoma in general is poor. Most reports refer to younger individuals, aged from 7 to 46 years, and only 2 case reports could be found for patients older than 64 years. Here we present a very unusual case of angiosarcoma in a 81-year-old patient.
- 29 June 2011
- Published by Springer Nature in Virchows Archiv
- Vol. 459 (2) , 183-191
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
Intratumoral immune cells and ERCC1 expression are likely to play a role in the response of ovarian carcinoma to chemotherapy, but their impact on therapy outcome is still unclear. Therefore, 41 cases of optimally resected high grade serous ovarian carcinomas were examined retrospectively for stromal and intraepithelial lymphocyte populations and ERCC1 status in relation to response to platinum-based therapy. Based on RECIST criteria, 27 patients were classified as responsive and 14 as therapy resistant, respectively. Using immunohistochemistry for CD3, CD8, CD4, TIA1, MUM1 and FOX P3 on representative tumor sections, we quantitatively evaluated the intratumoral density of lymphocyte subpopulations. In addition, ERCC1 protein and mRNA expression were determined by immunohistochemistry using the Steffensen score and quantitative RT-PCR, respectively. Furthermore, ERCC1 SNP’s C8092A and codon 118 were analysed. Response to chemotherapy was significantly associated with higher numbers of stromal CD3+ (mean 21.33 lymphocytes/HPF versus 8.21 lymphocytes/HPF, p = 0.002) and CD8+ lymphocytes (mean 9.22 lymphocytes/HPF versus 4.57 lymphocytes/HPF, p = 0.013). Counts of intraepithelial CD3+ and CD8+ lymphocytes, stromal and intraepithelial FOXP3+ and TIA1+ cells, CD4+ lymphocytes, and MUM1+ plasma cells did not reach statistical significance. Neither ERCC1 protein expression (p = 0.232) nor SNPs codon 118 and C8092A of the ERCC1 gene (p = 0.269 and p = 0.543) showed an association with therapy response. The same was true for ERCC1 mRNA levels (p = 0.896), probably due to intratumoral lymphocyte contamination. In conclusion, the density of CD3+ and CD8+ T-cells in tumor stroma proved to be a significant predictor for response to platinum-based therapy, whereas examination of ERCC1 failed to identify therapy-responsive patients.
- 29 June 2011
- Published by Springer Nature in Virchows Archiv
- Vol. 459 (2) , 183-191
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
Intratumoral immune cells and ERCC1 expression are likely to play a role in the response of ovarian carcinoma to chemotherapy, but their impact on therapy outcome is still unclear. Therefore, 41 cases of optimally resected high grade serous ovarian carcinomas were examined retrospectively for stromal and intraepithelial lymphocyte populations and ERCC1 status in relation to response to platinum-based therapy. Based on RECIST criteria, 27 patients were classified as responsive and 14 as therapy resistant, respectively. Using immunohistochemistry for CD3, CD8, CD4, TIA1, MUM1 and FOX P3 on representative tumor sections, we quantitatively evaluated the intratumoral density of lymphocyte subpopulations. In addition, ERCC1 protein and mRNA expression were determined by immunohistochemistry using the Steffensen score and quantitative RT-PCR, respectively. Furthermore, ERCC1 SNP’s C8092A and codon 118 were analysed. Response to chemotherapy was significantly associated with higher numbers of stromal CD3+ (mean 21.33 lymphocytes/HPF versus 8.21 lymphocytes/HPF, p = 0.002) and CD8+ lymphocytes (mean 9.22 lymphocytes/HPF versus 4.57 lymphocytes/HPF, p = 0.013). Counts of intraepithelial CD3+ and CD8+ lymphocytes, stromal and intraepithelial FOXP3+ and TIA1+ cells, CD4+ lymphocytes, and MUM1+ plasma cells did not reach statistical significance. Neither ERCC1 protein expression (p = 0.232) nor SNPs codon 118 and C8092A of the ERCC1 gene (p = 0.269 and p = 0.543) showed an association with therapy response. The same was true for ERCC1 mRNA levels (p = 0.896), probably due to intratumoral lymphocyte contamination. In conclusion, the density of CD3+ and CD8+ T-cells in tumor stroma proved to be a significant predictor for response to platinum-based therapy, whereas examination of ERCC1 failed to identify therapy-responsive patients.
- 1 June 2011
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (6) , 399-402
Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases
- 1 June 2011
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (6) , 399-402
Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases
- Open Access
- 10 January 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 4
Lymphoepithelioma-like carcinoma of the vulva, an underrecognized entity? Case report with a single inguinal micrometastasis detected by sentinel node technique
This report describes an unusual EBV-negative lymphoepithelioma-like carcinoma of the vulva in a 73-year-old patient. The lesion was localised at the right minor labium and was resected by partial vulvectomy. A synchronous sentinel lymph node biopsy revealed a single micrometastasis in the right inguinal region, which prompted local radiotherapy. Follow-up nine months later showed only slight vulvar atrophy, without signs of local recurrence or distant metastases.
- 10 January 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 4
Open AccessLymphoepithelioma-like carcinoma of the vulva, an underrecognized entity? Case report with a single inguinal micrometastasis detected by sentinel node technique
This report describes an unusual EBV-negative lymphoepithelioma-like carcinoma of the vulva in a 73-year-old patient. The lesion was localised at the right minor labium and was resected by partial vulvectomy. A synchronous sentinel lymph node biopsy revealed a single micrometastasis in the right inguinal region, which prompted local radiotherapy. Follow-up nine months later showed only slight vulvar atrophy, without signs of local recurrence or distant metastases.
- 19 October 2010
- Published by Springer Nature in Virchows Archiv
- Vol. 458 (1) , 109-113
Paratesticular fibrous pseudotumor—an IgG4-related disorder?
Paratesticular fibrous pseudotumor (nodular periorchitis, inflammatory pseudotumor of the spermatic cord) is a rare, benign condition of unknown etiology characterized by solitary or multiple intrascrotal nodules composed of dense fibrous tissue with a variable, sometimes sparse inflammatory infiltrate. Based on certain similarities to other fibroinflammatory disorders characterized by infiltrates of IgG4-expressing plasma cells and recently subsumed under the heading of IgG4-mediated diseases, we investigated the plasma cell distribution and immunoglobulin isotypes in three cases of paratesticular fibrous and inflammatory pseudotumor. All three cases showed a high number of IgG4-positive plasma cells with an IgG4 to IgG ratio of 44–48%. This finding indicates that paratesticular fibrous pseudotumor might belong to the growing list of IgG4-related diseases, which by now includes such diverse entities as retroperitoneal fibrosis, sclerosing pancreatitis and cholangitis, Riedel’s thyroiditis, or sclerosing sialadenitis.
- 19 October 2010
- Published by Springer Nature in Virchows Archiv
- Vol. 458 (1) , 109-113
Paratesticular fibrous pseudotumor—an IgG4-related disorder?
Paratesticular fibrous pseudotumor (nodular periorchitis, inflammatory pseudotumor of the spermatic cord) is a rare, benign condition of unknown etiology characterized by solitary or multiple intrascrotal nodules composed of dense fibrous tissue with a variable, sometimes sparse inflammatory infiltrate. Based on certain similarities to other fibroinflammatory disorders characterized by infiltrates of IgG4-expressing plasma cells and recently subsumed under the heading of IgG4-mediated diseases, we investigated the plasma cell distribution and immunoglobulin isotypes in three cases of paratesticular fibrous and inflammatory pseudotumor. All three cases showed a high number of IgG4-positive plasma cells with an IgG4 to IgG ratio of 44–48%. This finding indicates that paratesticular fibrous pseudotumor might belong to the growing list of IgG4-related diseases, which by now includes such diverse entities as retroperitoneal fibrosis, sclerosing pancreatitis and cholangitis, Riedel’s thyroiditis, or sclerosing sialadenitis.